MedPath

To evaluate the performance of the Trifectaâ?¢ Valve by Echocardiography in the Indian patient populatio

Phase 4
Conditions
Health Condition 1: null- Aortic Valve failure
Registration Number
CTRI/2014/02/004434
Lead Sponsor
St Jude Medical India Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1. Subject successfully implanted with SJM TrifectaTM Valve within the last 7 days.

2. Subject (or legal guardian) has given written informed consent for participation prior to enrollment

3. Subject is willing to undergo all study procedures and adhere to data collection and follow-up requirements

4. Subject has adequate echocardiographic images to measure hemodynamic performance of the SJM TrifectaTM valve.

Exclusion Criteria

1. Subject requires replacement of the mitral, tricuspid or pulmonary valve or has a pre-existing prosthetic valve

2. Subject undergoing renal dialysis

3. Subject has an active endocarditis (Subjects with previous endocarditis must have two documented negative blood culture results prior to enrollment)

4. Subject is currently participating in the study of an clinical investigational drug or device

5. Preoperative evaluation indicated other significant cardiovascular abnormalities such as aortic dissection or ventricular aneurysm.

6. Subject is pregnant or planning to become pregnant during the study period.

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the hemodynamic performance of the Trifectaâ?¢ valve as per the echocardiography parameters. The Mean, standard deviation, minimum and maximum values for mean gradient, peak gradient, effective orifice area, effective orifice area index, cardiac output, cardiac index, and performance index. The incidence/severity of aortic insufficiency (Percentage of subjects) as determined by echocardiography by location (central and paravalvular leak) will also be collected and recorded.Timepoint: 12 Months
Secondary Outcome Measures
NameTimeMethod
â?¢ Percentage of subjects in each NYHA functional classification at baseline (preoperatively) and at follow-up intervals, changes in their NYHA functional classification status - the percentage of subjects improving, not changing, or worsening in NYHA functional classification at each follow-up time point. <br/ ><br>â?¢ Proportion of structural valve deterioration <br/ ><br>â?¢ Adverse events during the follow up period <br/ ><br>Timepoint: 12 Months
© Copyright 2025. All Rights Reserved by MedPath